[Comment] PML risk and natalizumab: the elephant in the room

Natalizumab is one of the most effective therapies currently available for relapsing-remitting multiple sclerosis.1 With the exception of rare hypersensitivity reactions, monthly intravenous infusions are well tolerated and, for most patients, treatment is not associated with an increase in infections.2 But, for unknown reasons, progressive multifocal leukoencephalopathy (PML), an opportunistic, disabling, and life-threatening disease caused by the John Cunningham virus (JCV), is associated with natalizumab treatment.

Original Article: [Comment] PML risk and natalizumab: the elephant in the room

More From BioPortfolio on "[Comment] PML risk and natalizumab: the elephant in the room"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications